|
de Bono JS, Williams A, Melero I, Jayaram A, Hawley JE, Doger de Speville B, Moreno I, Castellano D, Reig O, Knapen DG, Anguera G, Martinez J, Gort E, de Jonge M, Alonso-Romero JL, Boni V, Perez-Gracia JL, Falcon A, de Groot DJ, Pierce AJ, Leishman AJ, Lloyd P, Bartlett PD, Bland-Ward P, Chau A, Song M, Duffy K, Hashimoto K, de Vries E. A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody(R) against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors. Clin Cancer Res. 2025 Mar 17. doi: 10.1158/1078-0432.CCR-24-3581. Online ahead of print. PubMed PMID: 40094417.
AÑO: 2025; IF: 10.0
|
40094417
|
Li X, Zhang Y, Zhu C, Xu W, Hu X, Martinez DAS, Romero JLA, Yan M, Dai Y, Wang H. Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer. BMC Womens Health. 2024 Jan 13;24(1):38. doi: 10.1186/s12905-023-02871-6. PubMed PMID: 38218823; PubMed Central PMCID: PMC10787989.
AÑO: 2024; IF: 2.4
|
|
Llombart-Cussac A, Perez-Garcia JM, Ruiz Borrego M, Tolosa P, Blanch S, Fernandez-Ortega A, Urruticoechea A, Blancas I, Saura C, Rojas B, Bermejo B, Ponce Lorenzo J, Gion M, Cortez-Castedo P, Llabres E, Galve E, Cueva JF, Lopez A, Alonso-Romero JL, Gonzalez-Santiago S, Martinez de Duenas E, Ciruelos E, Martrat G, Gener P, Alcala-Lopez D, Sampayo-Cordero M, Gomez-Peralta F, Cortes J. Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2024 Apr 11;71:102520. doi: 10.1016/j.eclinm.2024.102520. eCollection 2024 May. PubMed PMID: 38638399; PubMed Central PMCID: PMC11024566.
AÑO: 2024; IF: 9.6
|
|
Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Aunon P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Perez-Moreno PD, Lopez-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA; coopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023 Sep;24(9):1029-1041. doi: 10.1016/S1470-2045(23)00268-1. Erratum In: Lancet Oncol. 2023 Nov;24(11):e425. doi: 10.1016/S1470-2045(23)00482-5. PubMed PMID: 37657462.
AÑO: 2023; IF: 41.6
|
|
Rosado-Jimenez L, Mestre-Terkemani Y, Garcia-Aliaga A, Marin-Vera M, Macias-Cerrolaza JA, Sarabia-Meseguer MD, Garcia-Hernandez MR, Zafra-Poves M, Sanchez-Henarejos P, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Variantes geneticas recurrentes y priorizacion de variantes de significado clinico desconocido asociadas al sindrome de cancer de mama y ovario hereditario en familias de la Region de Murcia. Adv Lab Med. 2023 Jul 10;4(3):288-297. doi: 10.1515/almed-2023-0032. eCollection 2023 Sep. Spanish. PubMed PMID: 38075173; PubMed Central PMCID: PMC10701495.
AÑO: 2023; IF: 1.0
|